NOWDiagnostics has raised USD 22.5 million in a Series B funding round led by DigitalDx Ventures, with participation from Labcorp Venture Fund and Kompass Kapital Management, among others.
The funds are planned to be used for commercializing its at-home diagnostic tests, developing new diagnostic technologies, recruiting purposes, and expanding its clinical research pipeline, which includes over 30 diagnostic tests.
NOWDiagnostics develops and manufactures rapid diagnostic tests for over-the-counter (OTC) and point-of-care (POC) settings. The company uses its proprietary "Touch to Test" technology to deliver rapid results using a small amount of capillary blood or saliva. The company's product line includes tests for infectious diseases, cardiac markers, and women’s health.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.